Kelly Gurra
Investor Relations
Replay available
Pacific Biosciences of California, Inc. (NASDAQ: PACB) Q4 2025 earnings conference call, held 2026-02-12. Replay captured from the company's public earnings webcast.

Investor Relations
President and Chief Executive Officer
Chief Financial Officer
Analyst, Guggenheim
Analyst, Wolfe Research
Analyst, Cantor
Analyst, Piper Sandler
Analyst, Front Research
Analyst, TD Cowen
Analyst, Stevens
Good day and welcome to PACBio's fourth quarter and full year 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad, and to answer your question, please press star then two. Please note that today's event is being recorded. I would now like to turn the conference over to Kelly Gurra with Investor Relations. Please go ahead. Good afternoon, and welcome to PacBio's fourth quarter and full year 2025 earnings conference call. Earlier today, we issued a press release outlining the financial results we'll be discussing on today's call, a copy of which is available on the Investors section of our website at www.pacb.com, or as furnished on Form 8K available on the Securities and Exchange Commission website at www.sec.gov. A copy of our earnings presentation is also available on the Investors section of our website. With me today are Christian Henry, President and Chief Executive Officer, and Jim Gibson, Chief Financial Officer. On today's call, we will make forward-looking statements, including, among others, statements regarding predictions, estimates, expectations, and guidance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause our actual results to differ materially from those projected or discussed. Please review our SEC filings, including our most recent form, 10Q and 10K, and our press releases to better understand the risks and uncertainties that could cause results to differ. We disclaim any obl...